Gary S C, Zerillo C A, Chiang V L, Gaw J U, Gray G, Hockfield S
Section of Neurobiology, Yale University School of Medicine, New Haven, CT 06510, USA.
Gene. 2000 Oct 3;256(1-2):139-47. doi: 10.1016/s0378-1119(00)00362-0.
BEHAB (Brain Enriched HyAluronan Binding)/brevican, a brain-specific member of the lectican family of chondroitin sulfate proteoglycans (CSPGs), may play a role in both brain development and human glioma. BEHAB/brevican has been cloned from bovine, mouse and rat. Two isoforms have been reported: a full-length isoform that is secreted into the extracellular matrix (ECM) and a shorter isoform with a sequence that predicts a glycophosphatidylinositol (GPI) anchor. Here, we report the characterization of BEHAB/brevican isoforms in human brain. First, BEHAB/brevican maps to human chromosome 1q31. Second, we report the sequence of both isoforms of human BEHAB/brevican. The deduced protein sequence of full-length, secreted human BEHAB/brevican is 89.7, 83.3 and 83.2% identical to bovine, mouse and rat homologues, respectively. Third, by RNase protection analysis (RPA) we show the developmental regulation of BEHAB/brevican isoforms in normal human cortex. The secreted isoform is highly expressed from birth through 8years of age and is downregulated by 20years of age to low levels that are maintained in the normal adult cortex. The GPI isoform is expressed at uniformly low levels throughout development. Fourth, we confirm and extend previous studies from our laboratory, here demonstrating the upregulation of BEHAB/brevican mRNA in human glioma quantitatively. RPA analysis shows that both isoforms are upregulated in glioma, showing an approximately sevenfold increase in expression over normal levels. In contrast to the developmental regulation of BEHAB/brevican, where only the secreted isoform is regulated, both isoforms are increased in parallel in human glioma. The distinct patterns of regulation of expression of the two isoforms suggest distinct mechanisms of regulation of BEHAB/brevican during development and in glioma.
脑富集透明质酸结合蛋白(BEHAB)/短蛋白聚糖是硫酸软骨素蛋白聚糖(CSPG) lectican家族的一个脑特异性成员,可能在脑发育和人类胶质瘤中都发挥作用。BEHAB/短蛋白聚糖已从牛、小鼠和大鼠中克隆出来。已报道有两种异构体:一种全长异构体分泌到细胞外基质(ECM)中,另一种较短的异构体,其序列预测有糖基磷脂酰肌醇(GPI)锚定。在此,我们报告人脑BEHAB/短蛋白聚糖异构体的特征。首先,BEHAB/短蛋白聚糖定位于人类染色体1q31。其次,我们报告了人类BEHAB/短蛋白聚糖两种异构体的序列。推导的全长分泌型人类BEHAB/短蛋白聚糖的蛋白质序列与牛、小鼠和大鼠同源物的同一性分别为89.7%、83.3%和83.2%。第三,通过核糖核酸酶保护分析(RPA),我们展示了正常人类皮质中BEHAB/短蛋白聚糖异构体的发育调控。分泌型异构体从出生到8岁高度表达,到20岁时下调至低水平,并在正常成人皮质中维持该水平。GPI异构体在整个发育过程中均以均匀的低水平表达。第四,我们证实并扩展了我们实验室之前的研究,在此定量证明了人类胶质瘤中BEHAB/短蛋白聚糖mRNA的上调。RPA分析表明,两种异构体在胶质瘤中均上调,表达水平比正常水平增加约7倍。与BEHAB/短蛋白聚糖的发育调控不同,在发育调控中只有分泌型异构体受到调控,而在人类胶质瘤中两种异构体平行增加。两种异构体表达调控的不同模式表明BEHAB/短蛋白聚糖在发育和胶质瘤过程中有不同的调控机制。